NASCOBAL (cyanocobalamin) by Accord Biopharma is 12 can be converted to coenzyme b 12 in tissues, and as such is essential for conversion of methylmalonate to succinate and synthesis of methionine from homocysteine, a reaction which also requires folate. First approved in 2005.
Drug data last refreshed 5h ago · AI intelligence enriched 1mo ago
NASCOBAL is a nasal spray formulation of cyanocobalamin (vitamin B12) approved in 2005 for treating B12 deficiency. It works by replenishing cobalamin levels, which are essential for methylmalonate conversion, methionine synthesis, and maintaining reduced sulfhydryl groups in enzyme systems critical for fat, carbohydrate, and protein metabolism. The nasal route provides an alternative to intramuscular injection for patients requiring B12 supplementation.
Minimal Part D spending and claim volume indicate a niche product with limited commercial scale; expect small, stable regional teams focused on specialty pharmacy and patient adherence.
12 can be converted to coenzyme B 12 in tissues, and as such is essential for conversion of methylmalonate to succinate and synthesis of methionine from homocysteine, a reaction which also requires folate. In the absence of coenzyme B 12 , tetrahydrofolate cannot be regenerated from its inactive…
Vitamin B12
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Effect of Methylcobalamin and Cyanocobalamin Consumption on Vitamin B12 Nutritional Status
Characterization of Cyanocobalamin in Healthy Voluteers After Intranasal and Intramuscual Administration
Worked on NASCOBAL at Accord Biopharma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on NASCOBAL offers limited career growth given its LOE status and minimal commercial scale; positions are typically regional, focused on niche specialty pharmacy channels and patient adherence programs. Career advancement is constrained by the product's mature lifecycle and modest market presence.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/mo